MicroPET of tumor integrin αvβ3 expression using 18F-labeled PEGylated tetrameric RGD peptide ( 18F-FPRGD4)

Journal of Nuclear Medicine

Volumn 48, Issue 9, 2007, Pages 1536-1544

  Wu, Zhanhong ^a,b   Li, Zi Bo ^a,b   Chen, Kai ^a   Cai, Weibo ^a   He, Lina ^a   Chin, Frederick T ^a   Li, Fang ^b   Chen, Xiaoyuan ^a  

^a STANFORD UNIVERSITY   (United States)

^b PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

18F; Integrin v 3; MicroPET; PEGylation; Tetrameric RGD peptide

Indexed keywords

AMINO ACID; ARGINYLGLYCYLASPARTIC ACID; BENZOIC ACID DERIVATIVE; FLUORINE 18; FLUOROBENZENE; FLUOROBENZOYLAMINO 3,6,9 TRIOXAUNDECANOIC ACID GLUTAMYLBIS[GLUTAMYL [BIS (CYCLOARGINYLGLYCYLASPARTYL DEXTRO TYROSYLLYSINE)]] F 18; GLUTAMIC ACID; MACROGOL; PEPTIDE E; SUCCINIMIDE DERIVATIVE; TETRAMER; UNCLASSIFIED DRUG; UNDECANOIC ACID; VITRONECTIN RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RADIOASSAY; RADIOCHEMISTRY; REACTION TIME; TUMOR MODEL; XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; FEMALE; FLUORINE RADIOISOTOPES; HUMANS; INTEGRIN ALPHAVBETA3; MALE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; POSITRON-EMISSION TOMOGRAPHY; TRANSPLANTATION, HETEROLOGOUS;

EID: 34548580354     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.107.040816     Document Type: Article

References (39)

1. v-integrin, enter the cells by independent endocytic pathways. Lab Invest. 2001;81:1615-1626.
2. Cheng YF, Kramer RH. Human microvascular endothelial cells express integrin-related complexes that mediate adhesion to the extracellular matrix. J Cell Physiol. 1989;139:275-286.
3. Hwang R, Varner J. The role of integrins in tumor angiogenesis. Hematol Oncol Clin North Am. 2004;18:991-1006.
4. 3 subunit with tumor progression. Cancer Res. 1990;50:6757-6764.
5. 5 integrin expression in glioma periphery. Neurosurgery. 2001;49:380-389; discussion 390.
6. 3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest. 1995;96:1815-1822.
7. 3. Biotechniques. 2005;39:S6-S17.
8. 3 expression. Mini Rev Med Chem. 2006;6:227-234.
9. 3 targeted radiotracers for tumor imaging. Mol Pharm. 2006;3:472-487.
10. 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res. 2001;61:1781-1785.
11. 18F-galacto-RGD in cancer patients. J Nucl Med. 2005;46:1333-1341.
12. 3 expression in man. Clin Cancer Res. 2006;12:3942-3949.
13. 3 expression. J Nucl Med. 2006;47:763-769.
14. 18F-galacto-RGD. J Nucl Med. 2005;46:184-189.
15. Thumshirn G, Hersel U, Goodman SL, Kessler H. Multimeric cyclic RGD peptides as potential tools for tumor targeting: solid-phase peptide synthesis and chemoselective oxime ligation. Chemistry (Easton). 2003;9:2717-2725.
16. 18F-labeled dimeric RGD peptide. Mol Imaging. 2004;3:96-104.
17. 64Cu-labeled tetrameric RGD peptide. J Nucl Med. 2005;46:1707-1718.
18. 64Cu-labeled dimeric RGD peptides. Mol Imaging Biol. 2004;6:350-359.
19. 18F-FRGD2. J Nucl Med. 2006;47:113-121.
20. 3 integrin expression. J Nucl Med. 2006;47:1172-1180.
21. Mammen M, Chio S-K, Whitesides GM. Polyvalent interactions in biological systems: implications for design and use of multivalent ligands and inhibitors. Angew Chem Int Ed Engl. 1998;37:2755-2794.
22. 3 expression in living mice. Bioconjug Chem. 2005;16:1433-1441.
23. 64Cu-labeled RGD peptide. Bioconjug Chem. 2004;15:41-49.
24. 18F-Labeled RGD peptide: initial evaluation for imaging brain tumor angiogenesis. Nucl Med Biol. 2004;31:179-189.
25. Muller WJ, Sinn E, Pattengale PK, Wallace R, Leder P. Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell. 1988;54:105-115.
26. 3 integrin expression. Eur J Nucl Med Mol Imaging. May 5, 2007 [Epub ahead of print].
27. 3 receptor antagonists for tumor imaging and radiotherapy. Cancer Biother Radiopharm. 2003;18:627-641.
28. 99mTc-labeled quinolin-4-one peptidomimetics as ligands for the vitronectin receptor: potential tumor imaging agents. Bioconjug Chem. 2006;17:1294-1313.
29. 3 receptor antagonist: different but biologically equivalent. Bioconjug Chem. 2004;15:235-241.
30. 89Y-TA138. J Cardiovasc Pharmacol. 2005;45:109-113.
31. Janssen M, Oyen WJ, Massuger LF, et al. Comparison of a monomeric and dimeric radiolabeled RGD-peptide for tumor targeting. Cancer Biother Radiopharm. 2002;17:641-646.
32. 3-integrin expression. J Nucl Med. 2004;45:1776-1783.
33. Harris JM, Martin NE, Modi M. Pegylation: a novel process for modifying pharmacokinetics. Clin Pharmacokinet. 2001;40:539-551.
34. Walsh S, Shah A, Mond J. Improved pharmacokinetics and reduced antibody reactivity of lysostaphin conjugated to polyethylene glycol. Antimicrob Agents Chemother. 2003;47:554-558.
35. Behr TM, Goldenberg DM, Becker W. Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: present status, future prospects and limitations. Eur J Nucl Med. 1998;25:201-212.
36. Waldner C, Heise G, Meyer-Kirchrath J, Schror K, Grabensee B, Heering P. Selective cyclooxygenase-2 inhibition upregulates renal cortical alpha V integrin expression. Nephron Exp Nephrol. 2003;93:e72-e79.
37. 1 catalyzed 1,3-dipolar cycloaddition. Tetrahedron Lett. 2006;47:6881-6884.
38. 18F]fluorotropapride, two specific D2 receptor ligands for positron emission tomography: N.C.A. syntheses and animal studies. Int J Rad Appl Instrum [A]. 1992;43:1265-1274.
39. 18F-labeled RGD and octreotide analogs. J Nucl Med. 2004;45:892-902.